All In Biotech

Drug Trial Radar · NCT05331859

Topical Insulin Versus Autologous Serum After Corneal Surgeries

Topical Insulin Versus Autologous Serum and Enhanced Corneal Epithelial Healing After Keratorefractive Surgeries

Last checked: Nov 19, 2026Latest source record: Apr 22, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

250

Planned (sponsor's estimate)

Start

May 2022

Primary completion

Aug 2022

Study completion Sep 2022

Sponsor

Lead sponsor
Benha UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Apr 18, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
Double (participant, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The aim of the study is to test whether use of topical insulin or autologous serum eye-drops can promote corneal epithelial healing following photorefractive keratectomy (PRK).

Conditions

  • Corneal Epithelial Wound

Interventions

  • InsulinDrug

    Topical insulin drops will be prepared by diluting 1 unit of rapid-acting insulin per 1 mL of an artificial tear with a propylene glycol base. Drops will be preserved at low temperature (2ºC) and applied four times a day.

  • autologous serum (AS)Drug

    Whole blood (20 ml) wll be procured by venipuncture, centrifuged at 1,500 revolutions per minute (relative centrifugal force of 25.15 × g) for 10 minutes. AS drops will be carefully prepared under a laminar airflow cabinet, and diluted with artificial tears (Systane ultra; Alcon) to 20%. AS drops will be prepared on the day of surgery and patients will be asked to keep AS drops refrigerated at about 4C.

  • conventionalDrug

    Topical moxifloxacin 0.5% (Vigamox; Alcon Laboratories) four times per day, artificial tears (Systane ultra; Alcon) every two hours, Dexamethasone 0.1% (Maxidex; Alcon Laboratories) four times daily for one month then fluorometholone 0.1% (Efemyo; Orchidia Laboratories) four times daily for another two to four weeks depending on refraction and haze level.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Duration for the corneal surface to completely re-epithelialize.Time frame: up to 6 weeks
  2. Grade of postoperative corneal hazeTime frame: 6 weeks

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Benha University

    Banhā, Egypt

  • Ebsar Eye Centre

    Banhā, Kalyobeya, Egypt

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.